Expands Services, Offers Absolute Sample Protection
(Seattle, Wash.; Feb. 3, 2016) - LabConnect, a leading provider of highly customized global central laboratory services to biopharmaceutical, medical device and contract research organizations, has built a new biorepository facility to expand services and better meet the evolving needs of the industry.
LabConnect’s new, 5,000-square-foot biorepository in Johnson City, Tenn., features space for ambient, refrigerated, cold (-20C) and ultra-low temperature (-70C to -80C) storage as well as liquid nitrogen vapor phase storage (-190C).
“Proper sample management is essential to both today’s and tomorrow’s clinical trials,” said Eric Hayashi, LabConnect president and CEO. “Researchers depend on the integrity and availability of their stored biospecimens to retest them to verify trends or unexpected results, or for later retrieval to support specific biomarker research.”
With storage capacity for more than 8 million samples, LabConnect ensures the integrity of samples as well as business continuity with fully validated and mapped backup freezers and generators, redundant HVAC systems, whole building and biorepository security systems and a temperature monitoring system for all freezers and refrigerators with a 21 CFR Part 11 compliant audit trail.
“There are many biorepositories, but LabConnect’s facility is truly state-of-the art, using the most advanced technology available to provide the best protection in the industry for biospecimens,” said George Lewis, senior engineering technician at Johnson Controls, which supplies equipment to the Johnson City facility.
Additionally, through its SampleGISTICS™ system, LabConnect tracks sample locations and consolidates data within a centralized database accessible to researchers 24/7.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.